Chromadex Corp
NASDAQ:CDXC
Chromadex Corp
NASDAQ:CDXC
Price:
3.46 USD
0.58%
Updated:
Apr 29, 2024
P/B
Price to Book Value
Price to Book Value
9.1
Current
5.4
Median
2.5
Industry
Higher
than median
Higher
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=9.1
Market Cap
/
259.4m
Book Value of Equity
28.5m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| US |
|
Chromadex Corp
NASDAQ:CDXC
|
259.4m USD | 9.1 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.9B USD | 4.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
184B USD | 3.4 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.9B USD | 7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.6B CHF | 4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.8B USD | 6.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.2T KRW | 5.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | -179.9 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.2B USD | 9.1 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
25.3B USD | 2.7 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.3B EUR | 5 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
